<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069353</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13060260</org_study_id>
    <nct_id>NCT02069353</nct_id>
  </id_info>
  <brief_title>Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest</brief_title>
  <official_title>Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Elmer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laerdal Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac arrest is the most common cause of death in the United States and as many as 590,000
      Americans suffering a cardiac arrest each year. Despite advances in care, as many as 50 to
      89% of patients who are resuscitated after a cardiac arrest die in the hospital. Brain injury
      is the most common cause of death and disability after cardiac arrest. The investigators use
      advanced brain monitoring in patients who are at high risk of death after cardiac arrest,
      with the goal of preventing ongoing brain injury. The most common problem the investigators
      have observed is low oxygen levels in the brain, which is often very difficult to treat.

      In this study, the investigators plan to use two additional brain monitors in the care of
      these high risk patients: a monitor for seizures and a monitor of the amount of blood flow in
      the brain. The investigators will use these to detect and treat potential causes of low brain
      oxygen levels. The main hypotheses are that electrical events in the brain such as seizures
      and &quot;spreading depolarizations&quot; will occur during times of low brain tissue oxygen level, and
      that treating these events and low blood flow will reduce the rate of low brain oxygen
      levels.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spreading Depolarizations</measure>
    <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occult Seizures</measure>
    <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
    <description>Seizures detected by intracortical EEG but not surface EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral Hypoperfusion</measure>
    <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Bleeding</measure>
    <time_frame>Participants will be followed for the duration of the initial hospitalization, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitor-associated Infection</measure>
    <time_frame>Participants will be followed for the duration of the initial hospitalization, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Malfunction</measure>
    <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Cardiac arrest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)</intervention_name>
    <arm_group_label>Cardiac arrest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</intervention_name>
    <arm_group_label>Cardiac arrest</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk survivors of cardiac arrest

          -  Decision by potential subject's clinical team to use our institutional standard
             invasive, multimodal neurologic monitoring for post-arrest care

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>September 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2019</results_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jonathan Elmer</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Cardiac arrest</keyword>
  <keyword>Neurological injury</keyword>
  <keyword>Seizures</keyword>
  <keyword>Spreading depolarizations</keyword>
  <keyword>Cerebral hypoperfusion</keyword>
  <keyword>Brain tissue hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02069353/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardiac Arrest</title>
          <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cardiac Arrest</title>
          <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spreading Depolarizations</title>
        <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Arrest</title>
            <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
          </group>
        </group_list>
        <measure>
          <title>Spreading Depolarizations</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occult Seizures</title>
        <description>Seizures detected by intracortical EEG but not surface EEG</description>
        <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Arrest</title>
            <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
          </group>
        </group_list>
        <measure>
          <title>Occult Seizures</title>
          <description>Seizures detected by intracortical EEG but not surface EEG</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cerebral Hypoperfusion</title>
        <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Arrest</title>
            <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Hypoperfusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Bleeding</title>
        <time_frame>Participants will be followed for the duration of the initial hospitalization, an expected average of 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Arrest</title>
            <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Bleeding</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monitor-associated Infection</title>
        <time_frame>Participants will be followed for the duration of the initial hospitalization, an expected average of 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Arrest</title>
            <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
          </group>
        </group_list>
        <measure>
          <title>Monitor-associated Infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Malfunction</title>
        <time_frame>Participants will be followed for the duration of invasive monitoring, an expected average of 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Arrest</title>
            <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
          </group>
        </group_list>
        <measure>
          <title>Device Malfunction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of index hospitalization, a median of 3 days.</time_frame>
      <desc>Patients were examined by a study investigator daily to assess for adverse events until death or discharge.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cardiac Arrest</title>
          <description>Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)
Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Elmer</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-647-9489</phone>
      <email>elmerjp@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

